Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Tolerability and Safety Common side effects were primarily gastrointestinal and occurred mainly during dose escalation phases
This figure significantly surpasses the benchmarks set by previous generations of medical weight loss treatments
The tablet is Wegovy, a once-daily 25 mg semaglutide tablet licensed for weight loss and approved by the MHRA in June 2026
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously a mechanism that may offer more pronounced hepatic benefits than existing agents such as semaglutide or tirzepatide
US$ 26.58
US$ 25.86
US$ 23.81
US$ 29.14
US$ 23.46
